Study of Intravenously Administered SNS-032 in Patients With Advanced B-lymphoid Malignancies
The purpose of this study is to assess the safety and tolerability of escalating doses of SNS-032, given in 3 weekly administrations per cycle and to identify a recommended Phase 2 dose.
B-lymphoid Malignancies|Chronic Lymphocytic Leukemia|Mantle Cell Lymphoma|Multiple Myeloma
DRUG: SNS-032 Injection
To assess the safety and tolerability of SNS-032, 1 year
To characterize the pharmacokinetic profile of SNS-032, 1 year|Identify a recommended Phase 2 dose and schedule of administration, 1 year
Other objectives of this study include measuring pharmacokinetics (how long the drug can be measured in the body) and identifying potential biomarkers.